ClinicalTrials.gg
RecruitingNCT06606119Updated Feb 6, 2026

The Role of Brain-Bone Marrow-Gut Interaction Following Major Trauma

An observational study in Trauma Injury, Trauma and Critical Illness, sponsored by University of Florida. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by University of Florida · Observational

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
275
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Accidental Injuries with a site in United States — 17 open to participants now, 19 under way, 1 of them phase 3. Accidental Injuries · United States.

Planned enrollment
6th of 21
275 · median 124
Started
2025
with 4 others
Observational
21 of 58
7 open now
Primary completion
2027-10
later than 12 of 18 live
Registered
53rd of 58
by date
Lead sponsor
5 of 58
University of Florida

Among the 58 studies in Accidental Injuries with a site in United States, this one is the 6th largest by planned enrollment of the 21 observational ones that give a count, is one of 5 that started in 2025, is one of 21 observational ones, reaches primary completion later than 12 of the 18 other live ones, and was the 53rd registered.

Accidental Injuries

128 studies on the registry are indexed under Accidental Injuries; 39 are open to participants now.

Browse Accidental Injuries studies →

Open to participants now

17 of the 58 studies in Accidental Injuries with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Accidental Injuries studies recruiting now, 11 (46%) set no upper age limit and 6 (25%) stop at 75 or younger; 5 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Accidental Injuries with a site in United States, or all of them as a file.
02

Study summary

Traumatic injury followed by critical illness provokes pathophysiologic changes in the bone marrow and the gut that contribute to persistent anemia and changes in the microbiome which significantly impact long-term recovery. This project will define the interactions between the stress, chronic inflammation, bone marrow dysfunction, and an altered microbiome which will provide a strong foundation for future clinical interventions to help improve outcomes following severe trauma.

Read the detailed description

Trauma remains the leading cause of death among people younger than 46 years of age and is the leading cause of years of potential life lost among those younger than 65. With more lives saved, trauma morbidity has increased, which has consequently revealed a lack of understanding of the impact of trauma survivorship on the patients' quality of life and long-term recovery. Severe injury when followed by chronic critical illness leads to persistent anemia, and the use of blood transfusions is associated with a linear increase in infectious complications. These conditions are due to prolonged bone marrow dysfunction associated with an exaggerated catecholamine response, chronic stress, and systemic inflammation. Our laboratory has conducted human research to establish that there are unique bone marrow transcriptomic differences related to inflammation, the innate immune response, and known inhibitors of erythropoiesis following trauma. The laboratory has also discovered that chronic stress after trauma contributes to persistent anemia with impaired iron and erythropoietin function along with the prolonged loss of hematopoietic stem progenitor cells (HSPC) from the bone marrow. Chronic stress after trauma also induces an altered microbiome with decreased alpha and beta diversity and changes in microbial composition leading to a persistent 'pathobiome'. All of these factors influence outcomes. We hypothesize that there is a unifying interaction between stress, inflammation, and the microbiome and this has an overall role in the regulation of HSPC and erythroid progenitor cell fate and function following trauma and critical illness. Therefore, the overarching goal for this study is to build upon this foundation and expand our understanding of HSPC fate and function following trauma, including examining interventions aimed at reducing stress/inflammation and restoring the microbiome, thus, improving long-term outcomes.

03

Conditions studied

  • Trauma Injury
  • Trauma
  • Critical Illness
  • Microbiome
  • Chronic Anemia
  • Acute Blood Loss Anemia

Keywords

  • Hematopoietic Stem Progenitor Cells
  • Bone Marrow Failure
  • Anemia
  • Gut Microbiome
  • Inflammation
  • Dysregulated Stress Response
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Acute Care Trauma ICU - Severe Blunt Trauma Orthopedic Injury Shock Orthopedic Clinic - Elective Hip Replacement

Eligibility criteria

Severe Trauma Cohort

Inclusion Criteria:

  1. All adults (age ≥18).
  2. Blunt trauma with an injury severity score > 15 and a long bone or pelvic fracture requiring open reduction internal fixation or intramedullary fixation
  3. Blunt trauma patients with shock, defined by either a systolic BP (SBP) \<90 mm Hg or base deficit (BD) ≥5 meq or lactate ≥ 2 mmol/L or active red blood cell or whole blood transfusion within 6h or arrival

Exclusion Criteria:

  1. Patients not expected to survive greater than 48 hours
  2. Prisoners
  3. Pregnancy
  4. Previous bone marrow transplantation
  5. Patients receiving chronic or therapies
  6. Patients with End Stage Renal Disease
  7. Patients with any pre-existing hematological disease
  8. Surgery for repair of injury is greater than seven days after admission to the hospital for trauma
  9. Burn injury greater than 20% TBSA

Elective Hip Cohort

Inclusion Criteria

  1. All adults (age ≥55).
  2. Patient undergoing elective hip repair for non-infectious reasons.
  3. Ability to obtain prior to operation.

Exclusion Criteria

  1. Patients not expected to survive greater than 48 hours
  2. Prisoners
  3. Pregnancy
  4. Previous bone marrow transplantation
  5. Patients receiving chronic corticosteroids or immunosuppression therapies
  6. Patients with End Stage Renal Disease
  7. Patients with any pre-existing hematological disease
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
275 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Major Trauma Injury

    Severe blunt trauma patients diagnosed with shock with a long bone or pelvic fracture requiring open reduction internal fixation or intramedullary fixation.

    Other: Data and tissue collection

  • Elective Hip Replacement

    Patients undergoing elective hip replacement surgery

    Other: Data and tissue collection

Interventions

  • OtherData and tissue collection

    Collection of bone marrow, blood, feces, medical record data, and patient response surveys.

06

What researchers measure

Primary outcomes

  1. Link the changes in HSPC and erythroid progenitor cell fate and function with sympathetic stress-induced changes establishing brain-bone marrow communication following trauma.

    The impact of the severity and duration of catecholamine secretion on the cellular biology of HSPCs and erythroid progenitor cells requires further detailed evaluation. At each stage of proliferation and differentiation, there is a complex interaction of cytokines, transcription factors, post-translational modification of histones, and miRs. Single-cell RNA-seq technologies using a novel second generation multi-omics technology, CITE-seq, will be used for identification of isolated HSPCs and erythroid progenitor cells. Such single cell sequencing technology is ideal for cell populations with a great deal of heterogeneity and is well-suited for bone marrow analysis. Isolated cells can then be characterized by their transcriptomic and epigenetic changes. We will also evaluate EVM cargo (specific proteins/RNA/miR) from both plasma and bone marrow to determine links to chronic stress exposure.

    Time frame: 3 years

  2. Determine the connection between changes in the microbiome with sympathetic stress-induced changes establishing gut-brain communication following trauma.

    Focusing on the effects of autonomic nervous system on gut function and immune responses, in the setting of sympathetic activation, a serial evaluation of the gut microbiota and their metabolic products (ex. SCFAs: butyrate, propionate, and acetate) will be performed in trauma patients. Correlation of microbial diversity and alterations of the taxonomic composition will be correlated with plasma markers of inflammation and clinical outcomes. Longitudinal study of the trauma pathobiome will elucidate clinical course patterns (recovery and CCI) with microbial composition. The unique biology of the microbiome in different sexes and age groups will require additional subgroup analysis.

    Time frame: 3 years

  3. Link changes in the microbiome with altered HSPC and erythroid progenitor cells fate establishing gut-bone marrow communication following trauma

    We will examine how stress-induced changes following trauma create a pathobiome that modulates HPSC differentiation and maintains altered erythroid progenitor function. The microbiota play a role in both lineage differentiation and also control systemic iron homeostasis by inhibiting intestinal absorption and increasing cellular iron storage. Bone marrow macrophages have a key role in late-stage erythropoiesis by supplying local iron to erythroblasts for hemoglobin production. Isolation of bone marrow macrophages and erythroblasts involved in EBIs and determination of local iron content will define microbiome-induced changes in terminal erythropoiesis.

    Time frame: 3 years

07

Study locations

3 of 3 sites recruiting
  • UF Academic Research Building
    Gainesville, Florida 32610, United States
    Recruiting
  • UF Health at Shands Hospital
    Gainesville, Florida 32610, United States
    Recruiting
    • Ruth Davis, BSN · Contactruth.davis@surgery.ufl.edu · 352-273-8759
    • Jennifer Lanz, MSN · Contact352-273-5497
    • Alicia Mohr, MD · Principal investigator
  • UF Laboratory of Inflammation Biology and Surgical Science and Shands Hospital at UF
    Gainesville, Florida 32610, United States
    Recruiting
    • Alicia L Mohr, MD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Oct 2027, 32 months after the start.

Of 33 non-industry observational studies under Accidental Injuries, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 60. This study's planned 32 months is above that.

Counting every sponsor, half of 39 studies reached it within 31 months; a quarter within 12 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2024
First posted
Sep 20, 2024
StartActual
Jan 24, 2025
Primary completionEst.
Oct 1, 2027
CompletionEst.
Oct 1, 2028
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06606119
Responsible party
Sponsor
First posted
Sep 20, 2024
Start date
Jan 24, 2025
Primary completion
Oct 1, 2027 (estimated)
Completion
Oct 1, 2028 (estimated)
Last update
Feb 6, 2026

Study contacts

Ruth Davis, BSN
Contact
ruth.davis@surgery.ufl.edu
352-273-8759
Jennifer Lanz, MSN
Contact
jennifer.lanz@surgery.ufl.edu
352-273-5497
Alicia Mohr, MD
principal investigator · University of Florida

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion